PATENT

RECEIVED CENTRAL FAX GENTER MAY 1 0 2006

I hereby certify that this paper is being facsimile transmitted to the United States Patent and Trademark Office on the date shown below.

Amy Yost
Date of Signature ____May 10, 2008

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Gunzburg et al.

Group Art Unit: 1632

<u>Serial No.: 10/758,772</u>

Examiner: Chen, Shin Lin

Filed: January 16, 2004

Docket No.: 1406/207

Confirmation No.: 6313

For: THE USE OF THE WAP OR MMTV REGULATORY SEQUENCES FOR TARGETED EXPRESSION OF LINKED HETEROLOGOUS GENES IN HUMAN MAMMARY CELLS, INCLUDING HUMAN MAMMARY CARCINOMA CELLS

* * * * * * * * * * * *

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97, and 1.98, applicants' undersigned attorney brings to the attention of the Patent and Trademark Office the following references. Form PTO-1449 are attached hereto.

Copies of the cited documents are of record in the file history of U.S. Patent Application Serial No. 09/035,596 filed on March 5, 1998. The above-captioned application claims priority to U.S. Patent Application Serial No. 09/035,596 under 35 U.S.C. § 120, and as per 37 C.F.R. § 1.98, no copies of these cited documents are believed to be required.

Serial No.: 10/758,772

Early passage of the subject application to issue is earnestly solicited.

Although it is believed that no fee is due, the Commissioner is hereby authorized to charge any fees associated with the filing of this correspondence to Deposit Account No. 50-0426.

Respectfully submitted,

JENKINS, WILSON, TAYLOR & HUNT, P.A.

Date: <u>05/10/2004</u>

Ву:

Arles A. Taylor, Jr.

Registration No. 39,395

AAT/acy

Enclosures

Customer No: 25297

FORM PTO-1449 U.S. Department of Commerce					Application No.:	10/758,772		
Patent and Trademark Office					Filing Date:	January 16, 2004		
! !-4 -5 D-		ata Oktob book and the				First Named Inventor:	Gunzburg	
LIST OF DO	cume	nts Cited by Applic	ant			Group:	1632	
						Examiner:	Chen, Shin Lin	
					Attorney Docket No.:	1406/207		
				U.S. PATE	ENT DO	CUMENTS		•
Examiner Initial	Cite No.	Document Number	Document Number Publication Date		Name of Patentee or Applicant of Cited Document		Pages, Columns, Lines, where relevant passages o relevant figures appear	
	1	6,241,982		В		er et al.		
	2	4,873,316			Meade et al.		·	
•			F	OREIGN PA	TENT	DOCUMENTS	<u> </u>	
Examiner Initials	Cite No.	Document Numbe (country code, no., k code (if known)	, no., kind		n Date	Name of Patentee or Applicant	Pages, columns, lines where relevant passages appear	Υ
•	3	WO 96/07748		3/14/199	3	GSF Forschungzentrum Unwelt		
	4	WO 94/29437		10/22/19	94	Univ. N.J. Med.		Γ
	5	WO 95/15334		6/8/1995		C.A. Pacific Med. Cancer		
	6	WO 94/05796		3/17/1994		American Natl. Red Cross		
	7	WO 89/11539		11/30/19	39	Sloan Kettering Inst. Cancer		
	8	WO96/28564		9/19/1996	3	Bovarian Nordic Res. Inst AS		
	9	WO 96/28563		9/19/1996	3	Bovarian Nordic		
	10	WO 97/13867		4/17/1997	7	Bovarian Nordic Res. Inst AS		

Page 2 of 3

	11	WO 97/35994	10/2/1997	Bovarian Nordic Res. Inst AS			
	12	WO 97/01357	1/16/1997	Bovarian Nordic Res. Inst AS			
			OTHER DO	CUMENTS			
Examiner Initials	Cite No.	Include Author (in CAPITAL	LETTERS), Title, Jo	umal, Date, Pertinent Pages, Etc.	Т		
	13	KOLB A.F. ET AL., "(And Biophys. Res. C	Characterization omm., 217(3) :1	n of a protein that bind a negative", <u>Biochen</u> 045-1052, 1995.	<u>1.</u>		
-	14	GRUNZBURG ET AL Biologicals, 23:5-12,	, "Retroviral ve 1995.	ectors directed to predefined cell types for	1		
	15	GRUNZBURG AND Med. Tod., 1:410-417	SALMONS, "Vir 7, 1995.	us vector design in gene therapy", Mol.			
	16	KOLB, A.F. ET AL, "I Cell. Biochem., 56:24	Negative regula 15-261, 1994,	tory element in the mammary specific", <u>J.</u>			
	17	HENNIGHAUSEN, L Biochem., 49;325-33	., "The prospect 2, 1992.	s for domesticating milk protein genes", <u>J. Ce</u>	<u>II.</u>		
	18	GRUNZBURG ET AL Endocricn., 5(1):123-	, "A mammary 133, 1991.	-specific promoter directs expression", Mol	_		
	19	<u>Virology</u> , 144:101-114, 1985.					
	20						
	21	VERMA ET AL., <u>Nature</u> 389 :239-242, September 1997.					
	22	ECK ET AL., "The Pharmacological basis of Therapeutics", Goodman & Gilman MacGraw-Kil, New York; 1:77-101, 1996.					
·	23	WILSON ET AL, <u>Investigative ophthalmology and visual science</u> , 36(1) :32-40, January 1995.					
24 ARCHER ET AL., Molecular Endocrinology, 8(9):1154-1162, Septen				nology, 8(9):1154-1162, September 1994.			
	25	SALMONS, B. AND B Research, 8:81-102,		urrent perspectives in the biology", <u>Virus</u>			
	26	MEHIGH ET AL., <u>Jou</u>	rnal of Animal S	Science, 71(3) :687-693, 1993.			
	27	GORECKI, D., Experi	Opin. Emergin	g Drugs, 6(2):187-198, 2001.			

Page 3 of 3

Investment in Research on Gene Therapy, 1995. 31 DRANOFF ET AL., Proc. Natl. Acad. Sci. USA, 90:3539-3543, 1993. 32 LEFEBRE ET AL, Molecular and Cellular Biology, 11(5):2529-2537, 1991. 33 PALEYANDA ET AL., transgenic Research, 3:335-343, 1994.		
186(1):426-431, 1992. ORKIN ET AL., Reports and Recommendations of the Panel to Assess the NII- Investment in Research on Gene Therapy, 1995. DRANOFF ET AL., Proc. Natl. Acad. Sci. USA, 90:3539-3543, 1993. LEFEBRE ET AL, Molecular and Cellular Biology, 11(5):2529-2537, 1991. PALEYANDA ET AL., transgenic Research, 3:335-343, 1994.	28	VERLANDER ET AL., Proc. Natl. Acad. Sci. USA, 89:12003-12007,1992.
Investment in Research on Gene Therapy, 1995. 31 DRANOFF ET AL., Proc. Natl. Acad. Sci. USA, 90:3539-3543, 1993. 32 LEFEBRE ET AL, Molecular and Cellular Biology, 11(5):2529-2537, 1991. 33 PALEYANDA ET AL., transgenic Research, 3:335-343, 1994.	29	RICKEETS ET AL., <u>Biochemical and Biophysical Research Communications</u> , 186(1) :426-431, 1992.
32 LEFEBRE ET AL, Molecular and Cellular Biology, 11(5):2529-2537, 1991. 33 PALEYANDA ET AL., transgenic Research, 3:335-343, 1994.	30	ORKIN ET AL., Reports and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy, 1995.
33 PALEYANDA ET AL., <u>transgenic Research</u> , 3:335-343, 1994.	31	DRANOFF ET AL., <u>Proc. Natl. Acad. Sci. USA</u> , 90:3539-3543, 1993.
	32	LEFEBRE ET AL, Molecular and Cellular Biology, 11(5):2529-2537, 1991.
04 0140 FT AL D.L. D. 05/01/00 00 4004	33	PALEYANDA ET AL., transgenic Research, 3:335-343, 1994.
34 SHAO ET AL. <u>Polym. Prepr.</u> , 35(2) :59-60, 1994.	34	SHAO ET AL, <u>Polym. Prepr.</u> , 35(2) :59-60, 1994.
35 AEBISCHER ET AL., <u>J. Biomech. Eng.</u> , 113(2) :178-183 1991.	35	AEBISCHER ET AL., <u>J. Biomech. Eng.</u> , 113(2) :178-183 1991.

EXAMINER _	DATE CONSIDERED
	initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office					Application No.:	10/758,772		
					Filing Date:	January 16, 2004		
List of D	ocume	ents Cited by Applic	ant			First Named Inventor:	Gunzburg	
		The one by Application	J			Group:	1632	_
						Examiner:	Chen, Shin Lin	_
			<u>-</u>			Attorney Docket No.:	1406/207	
	-,		_	U.S. PATE	ENT D	OCUMENTS		
Examiner Initial	Cite No.	Document Number	Publication Date		Name of Patentee or Applicant of Cited Document		Pages, Columns, Line where relevant passage relevant figures appe	es o
	1	6,241,982				er et al.	0 33 347	
	2	4,873,316				de et al.		
<u>,, </u>			F	OREIGN PA	TENT	DOCUMENTS		
Examiner Initials	xaminer Cite Document Number Publication			Name of Patentee or Applicant	Pages, columns, lines where relevant passages appear	7		
	3	WO 96/07748		3/14/1996		GSF Forschungzentrum Unwelt		
	4	WO 94/29437		10/22/199	94	Univ. N.J. Med.		-
	5	WO 95/15334		6/8/1995		C.A. Pacific Med. Cancer		<u> </u>
·	6	WO 94/05796		3/17/1994 11/30/1989 9/19/1996		American Natl. Red Cross		
	7	WO 89/11539				Sloan Kettering Inst. Cancer	_	
	8	WO96/28564				Bovarian Nordic Res. Inst AS		
	9	WO 96/28563		9/19/1996		Bovarian Nordic		
	10	WO 97/13867		4/17/1997		Bovarian Nordic Res. Inst AS		_

COPY

Page 2 of 3

					rage z of	3		
	11	WO 97/35994	10/2/1997	Bovarian Nordic Res. Inst AS		_		
	12	WO 97/01357	1/16/1997	Bovarian Nordic Res. Inst AS	-			
			OTHER DO	CUMENTS				
Examiner Initials	Cite No.	Include Author (in CAPITAL	LETTERS), Title, Jo	numal, Date, Pertinent Pages, Etc.		Т		
	13	KOLB A.F. ET AL., "(And Biophys. Res. Co	KOLB A.F. ET AL., "Characterization of a protein that bind a negative", <u>Biochem.</u> And Biophys. Res. Comm., 217(3):1045-1052, 1995.					
	14	GRUNZBURG ET AL Biologicals, 23:5-12,	., "Retroviral ve 1995.	ectors directed to predefined c	ell types for",			
	15	GRUNZBURG AND 8 Med. Tod., 1:410-417	GRUNZBURG AND SALMONS, "Virus vector design in gene therapy", Mol. Med. Tod., 1:410-417, 1995.					
	16	KOLB, A.F. ET AL, "N Cell. Biochem., 56:24	KOLB, A.F. ET AL, "Negative regulatory element in the mammary specific", J. Cell. Biochem., 56:245-261, 1994.					
	17	HENNIGHAUSEN, L., Biochem., 49;325-332	"The prospect 1, 1992.	s for domesticating milk protei	n genes", <u>J. Cell.</u>			
	18	GRUNZBURG ET AL Endocricn., 5(1):123-1	, "A mammary- 33, 1991.	specific promoter directs expr	ession", Mol.			
	19	SALMONS ET AL., " Production of mouse mammary tumor virus upon", Virology, 144:101-114, 1985.						
	20	PETITCLERC ET AL, "J. of Biotechnology, 40(3):169-178, June 1995.						
-	21	VERMA ET AL., <u>Nature</u> 389 :239-242, September 1997.						
	22	ECK ET AL., "The Pharmacological basis of Therapeutics", Goodman & Gilman MacGraw-Kil, New York; 1:77-101, 1996.						
	23	WILSON ET AL, <u>Investigative ophthalmology and visual science</u> , 36(1):32-40, January 1995.						
_	24	ARCHER ET AL., Mole	ecular Endocrin	ology, 8(9):1154-1162, Septer	mber 1994			
	25		JNZBURG. "Cu	rrent perspectives in the biolo	1			
	26	MEHIGH ET AL., Journ	nal of Animal So	cience, 71(3) :687-693, 1993.		\dashv		
	27			Drugs, 6(2):187-198, 2001.		-		
						H		

Page 3 of 3

	28	VERLANDER ET AL., <u>Proc. Natl. Acad. Sci. USA</u> , 89:12003-12007,1992.
	29	RICKEETS ET AL., <u>Biochemical and Biophysical Research Communications</u> , 186(1) :426-431, 1992.
	30	ORKIN ET AL., Reports and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy, 1995.
	31	DRANOFF ET AL., <u>Proc. Natl. Acad. Sci. USA</u> , 90 :3539-3543, 1993.
	32	LEFEBRE ET AL, Molecular and Cellular Biology, 11(5):2529-2537, 1991.
·	33	PALEYANDA ET AL., transgenic Research, 3:335-343, 1994.
	34	SHAO ET AL. <u>Polym. Prepr.</u> , 35(2) :59-60, 1994.
	35	AEBISCHER ET AL., <u>J. Biomech. Eng.</u> , 113(2) :178-183 1991.

EXAMINER DA	ATE CONSIDERED
-------------	----------------

^{*}Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.